While Hsp90 inhibitors, which indirectly activate HSF1, show promise in treating neurodegenerative diseases [97],[98], the beneficial effect was shown to be directly due to Hsp90 inhibition, which, in the case of tauopathies, reduces the functional cycling of kinases and thereby tau phosphorylation, minimizing its aggregation and toxicity [99],[100]. The gene discussed is HSP90AA1; the disease is tauopathy.